Currently, Phase II ROP is treated with methods to ablate the peripheral avascular retina, often with laser (6), or with intravitreal agents that interfere with the bioactivity of vascular endothelial growth factor (VEGF) (7–11). This evidence concerns the gene VEGFA and retinopathy of prematurity.